Cargando…

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246

BACKGROUND: p53 mutants contribute to the chronic inflammatory tumour microenvironment (TME). In this study, we address the mechanism of how p53 mutants lead to chronic inflammation in tumours and how to transform it to restore cancer immune surveillance. METHODS: Our analysis of RNA-seq data from T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaolei, Santos, Gema Sanz, Zhan, Yue, Oliveira, Mariana M. S., Rezaei, Shiva, Singh, Madhurendra, Peuget, Sylvain, Westerberg, Lisa S., Johnsen, John Inge, Selivanova, Galina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681866/ https://www.ncbi.nlm.nih.gov/pubmed/36138076 http://dx.doi.org/10.1038/s41416-022-01971-8

Ejemplares similares

Inhibition of p53 inhibitors: progress, challenges and perspectives
por: Sanz, Gema, et al.
Publicado: (2019)

Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes
por: Zhu, Jiawei, et al.
Publicado: (2020)

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
por: Zhan, Yue, et al.
Publicado: (2022)

p53-Dependent Repression: DREAM or Reality?
por: Peuget, Sylvain, et al.
Publicado: (2021)

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity
por: Zhou, Xiaolei, et al.
Publicado: (2021)

Identification and targeting of selective vulnerability rendered by tamoxifen resistance
por: Singh, Madhurendra, et al.
Publicado: (2020)

Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization
por: Aschtgen, Marie-Stéphanie, et al.
Publicado: (2022)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture
por: Rangel-Pozzo, Aline, et al.
Publicado: (2020)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

Piperlongumine and p53-Reactivator APR-246 Selectively Induce Cell Death in HNSCC by Targeting GSTP1
por: Hang, Wei, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data
por: Franco, Marcela, et al.
Publicado: (2019)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
por: Fang, Y., et al.
Publicado: (2022)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

PRIMA-1(met) (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
por: Li, Xiao-Lan, et al.
Publicado: (2015)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2022)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
por: Müller, Michael, et al.
Publicado: (2021)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants
por: Nagourney, Adam J., et al.
Publicado: (2023)

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
por: Liang, Yayun, et al.
Publicado: (2018)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4b1201cp3ot180niprqmefq0ro